Bio B2B 〉 Selective Search Results
Your Selection Setting ：Orthopedics / Musculoskeletal；
Selective Search Results :
Pipeline & Platform 7 record(s)；
The production platform is fully compliant with medical regulations (Good Tissue Practice, GTP) in Taiwan. We have three clinical trials are going in Taiwan by now including GXHPC1, GXNPC1 and GXCPC1, indications of liver cirrhosis, stroke and osteoarthritis, respectively. Three clinical trials are using adipose-derived stem cells (ADSCs) as cell source transplanted into local lesions. In addition
TLC599 is our proprietary BioSeizer formulation of dexamethasone sodium phosphate (DSP) designed to provide sustained pain management over an extended period of three months or more. TLC599 has the potential to enable patients to receive both immediate and sustained benefit from the local delivery of a highly potent and clinically validated steroid that typically has a very short half-life. Our
Complete and Comprehensive Design/Production Capabilities
United Orthopedic has had the privilege of supplying world class orthopedic joint replacements, till now, had helped over 230 thousand suffering patients gain back their mobility and quality of life. Through cooperation with international orthopedic surgeons and institutes, United Orthopedic continue innovate and develop new techniques and design to fulfill the demand of modern orthopedic community
Locking Plate System
Aplus, found in Taiwan in 2009, devotes itself to the research and development of orthopedic medical products. The Aplus team is known for its focus on, and innovation in, the orthopedic trauma field and the construction of a partnership among industry, academia, research circles, and the medical community.
PHN031 (Osteoporosis prevention)
Advantages of the productSelection of native plants for control the medicinal origin and qualityLong-term human experience show no drug- related toxicityThere are dual affects in enhancing bone formation index and restraining bone loss indexCharacteristic fingerprint to ensure superior quality controlWell-defined specifications to prove the consistency of quality among batches
TRIA11 is a biosimilar indicated for osteoporosis. The current global sales of the original product reaches to $1.7 billion. An injection pen is also developed to enhance the convenience of use. TRIA11 is planned to launch in EU first, and TSH Biopharm has consulted EMA for the development plan. TRIA11 is expected to move into clinical stage by the end of 2019.
AdvantageAdvantages include replacing complicated surgical procedures, such as harvesting cells from cartilage allografting, or bone marrow .Promoting the repair and functional regeneration of cartilage affected by degenerative OA, and improving patients' quality of life.Low immune risk